Cencora’s Volume Dips 36.59% to 331st Rank as Stock Rallies 0.65% on Wells Fargo’s Upgraded Target

On August 13, 2025, Cencora (COR) traded with a volume of $0.37 billion, a 36.59% decline from the previous day, ranking 331st in market activity. The stock closed up 0.65%, reflecting modest gains despite reduced liquidity.

Wells Fargo raised its price target for Cencora to $354 from $337, maintaining an Overweight rating. The adjustment follows strong core U.S. Healthcare performance, which offset weaker international results. Analysts cited improved fiscal 2025–2027 earnings forecasts, with adjusted EPS estimates increased by 0.6% to $15.93 in 2025 and 2.4% to $19.68 in 2027. The firm justified the valuation premium through Cencora’s execution in mergers and acquisitions and favorable industry conditions, despite recent market-driven volatility.

The stock’s 0.65% gain contrasts with broader market declines, as Cencora’s third-quarter earnings exceeded expectations (EPS of $4 vs. $3.84) and revenue hit $80.7 billion. However, post-earnings weakness highlighted sensitivity to macroeconomic shifts. With a "GOOD" financial health rating and a market cap of $56 billion, the company remains a focus for momentum-driven strategies.

A backtest of a strategy buying the top 500 stocks by daily trading volume and holding for one day from 2022 to 2025 yielded a 0.98% average daily return. Over 365 days, the total return was 31.52%, capturing short-term momentum while reflecting inherent market volatility and timing risks.